P/B
12
DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
$31.4B
Market Cap • 9/11/2026
1999
(27 years)
Founded
2005
(21 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
6,3
P/EBITDA
22,4
P/OCF
17,9
P/FCF
22,3
P/E
32,9
BVPS
6,6
EPS
2,5
Market Cap
Market Cap
31,4B
EV
30,8B
EV/Revenue
6,2
EV/EBITDA
21,9
EV/EBIT
27
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
3,4%
Total Yield
3,4%
Payout
0%
Retained Earnings
2,9B
Profitability
Gross Margin
62,5%
EBITDA Margin
28,2%
EBIT Margin
22,9%
Net Margin
20,1%
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
6,9%
Capex/D&A
130,1%
Capex/OCF
19,7%
SBC/OCF
9,3%
% PPE
25,8%
% Goodwill
0,4%
ROE
38,5%
ROIC
37,2%
Growth
CAGR Revenue 5Y
18%
CAGR Op. Income 5Y
27%
CAGR Net Income 5Y
10,1%
CAGR EPS 5Y
12,8%
CAGR OCF 5Y
33,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
1,7
Quick Ratio
1,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!